Related Experiment Video
Updated: Aug 17, 2025
10:41
Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity
Published on: February 17, 2017
8.1K
Aptamers Regulating the Hemostasis System
Anatoly A Vaganov1, Tatiana E Taranushenko1, Natalia A Luzan2,3
1Department of Pediatrics, Faculty of Medicine, Krasnoyarsk State Medical University, 660022 Krasnoyarsk, Russia.
Molecules (Basel, Switzerland)
|December 11, 2022
Summary
Aptamers, particularly G-rich nucleic acid aptamers, show promise for regulating the hemostasis system. These molecules can target clotting factors and platelet proteins, offering potential for new anticoagulants with fewer side effects.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- The hemostasis system is a complex network involving coagulation, anticoagulation, and fibrinolysis.
- Studying signaling pathways and developing selective drugs are crucial for hemostasis disorders.
- Molecular recognition elements are needed to modulate hemostasis system components.
Purpose of the Study:
- To review aptamers targeting the hemostasis system.
- To explore the structural and functional characteristics of these aptamers.
- To highlight their potential in correcting hemostasis system imbalances.
Main Methods:
- Literature review focused on aptamers and hemostasis.
- Analysis of aptamer structures, particularly G-quadruplexes.
- Examination of aptamer interactions with clotting factors and platelet proteins.
Main Results:
- Aptamers can act as ligands to block or activate hemostasis pathways.
- G-rich nucleic acid aptamers, often forming G-quadruplexes, recognize hemostasis components.
- Aptamers are investigated for treating thrombosis by targeting clotting factors and platelet proteins.
Conclusions:
- Aptamers offer a promising strategy for developing targeted anticoagulants.
- Their ability to selectively modulate hemostasis components suggests potential for reduced side effects.
- Further research into aptamer structure-function relationships can lead to novel therapeutic agents.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
827
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
827
01:05Introduction to Hemostasis
8.5K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.5K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
8.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.7K
01:22Formation of the Platelet Plug
6.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.8K
01:16Clot Retraction and Fibrinolysis
6.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.6K
01:24Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K